BNP Paribas Acquires 16,150 Shares of Zoetis Inc. $ZTS

BNP Paribas grew its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 10.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 169,600 shares of the company’s stock after purchasing an additional 16,150 shares during the period. BNP Paribas’ holdings in Zoetis were worth $24,485,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. North Star Asset Management Inc. increased its position in Zoetis by 4.9% during the 2nd quarter. North Star Asset Management Inc. now owns 1,441 shares of the company’s stock valued at $225,000 after buying an additional 67 shares in the last quarter. Bank of Nova Scotia Trust Co. boosted its holdings in Zoetis by 4.6% in the second quarter. Bank of Nova Scotia Trust Co. now owns 1,692 shares of the company’s stock worth $264,000 after acquiring an additional 74 shares in the last quarter. Summit Place Financial Advisors LLC boosted its holdings in Zoetis by 0.4% in the third quarter. Summit Place Financial Advisors LLC now owns 19,369 shares of the company’s stock worth $2,834,000 after acquiring an additional 76 shares in the last quarter. First County Bank CT grew its stake in shares of Zoetis by 5.4% in the third quarter. First County Bank CT now owns 1,535 shares of the company’s stock worth $225,000 after acquiring an additional 79 shares during the last quarter. Finally, CWA Asset Management Group LLC grew its stake in shares of Zoetis by 1.1% in the third quarter. CWA Asset Management Group LLC now owns 7,236 shares of the company’s stock worth $1,059,000 after acquiring an additional 80 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Trading Up 0.1%

Shares of NYSE:ZTS opened at $115.62 on Friday. The company has a market cap of $48.81 billion, a P/E ratio of 19.21, a PEG ratio of 1.76 and a beta of 0.95. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. Zoetis Inc. has a 1 year low of $114.47 and a 1 year high of $172.23. The stock’s fifty day moving average price is $125.34 and its 200-day moving average price is $131.75.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. During the same period last year, the company earned $1.40 EPS. Zoetis’s revenue for the quarter was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Sell-side analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

Analysts Set New Price Targets

ZTS has been the subject of several recent analyst reports. Barclays initiated coverage on Zoetis in a research report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price target for the company. Piper Sandler restated a “neutral” rating and set a $135.00 price objective (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Bank of America upped their target price on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research note on Friday, February 13th. Finally, William Blair reiterated an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Six investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.